PropThink: Ziopharm – Making Progress in Advanced Melanoma
[ACN Newswire] – By David SobekWhile investors have been focusing their attention on palifosfamide and the upcoming phase III data, Ziopharm (NASDAQ:ZIOP) released some initial phase I data of Ad-RTS IL-12 in advanced … more
View todays social media effects on ZIOP
View the latest stocks trending across Twitter. Click to view dashboard